Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer
NCT00039676 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1836
Last updated 2026-05-01
Summary
Background:
* Individuals may be prone to develop blood or lymph node cancers (leukemia or lymphoma) for a variety of reasons, including genetic predisposition to these cancers, environmental exposures or other medical conditions.
* Studies of people and families at high risk of cancer often lead to clues about their cause that may also be important regarding the sporadic occurrence of these cancers in the general population.
* Identifying genetic or environmental factors that play a role in the development of these diseases may be important in developing prevention trials, screening programs and treatments.
Objectives:
* Describe the cancers and other conditions in families with blood or lymph node cancer.
* Find and describe genes that may cause blood and lymph node cancer, and understand how they work in families.
* Use laboratory methods to try to determine if it is possible to identify who is at highest risk of blood or lymph node cancer.
* Test how genes act with other factors to alter the risk of disease, its severity or its manifestations in families.
Eligibility:
* Individuals of any age with a personal or family history of a blood or lymph node cancer.
* Individuals with a personal or family history of medical conditions or environmental exposures that may predispose to blood or lymph node cancer.
Design:
* Participants complete questionnaires about their personal and family medical history and provide consent for researchers to review their medical records and pathology materials related to their care and those of deceased relatives with blood or lymph node cancer, tumors, or other related illnesses for whom they are the legally authorized representative.
* Participants donate a sample of blood or cheek cells, or a lock of hair for genetic studies.
* Patients may also be evaluated at the NIH Clinical Center by one or more of the following specialists: cancer doctor or blood specialist, medical geneticist, research nurses or clinical social worker. They may have blood and urine tests and a cheek swab or mouth wash to collect cheek cells. Some patients may also be asked to have x-rays and routine imaging, such as CT scans or ultrasound tests, cell surface markers, skin biopsy, and, with special consents, bone marrow biopsy, MRI or PET scans, apheresis or fluorescein angiography and photography.
Conditions
- Waldenstrom Macroglobulinemia
- Chronic Lymphocytic Leukemia
- Hodgkin Disease
- NonHodgkin Lymphoma
- Mixed Lymphoproliferative Disease
Sponsors & Collaborators
-
National Cancer Institute (NCI)
lead NIH
Principal Investigators
-
Douglas R Stewart, M.D. · National Cancer Institute (NCI)
Eligibility
- Min Age
- 11 Months
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2002-07-08
Countries
- United States
Study Locations
More Related Trials
-
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
NCT00131014 ·Status: RECRUITING
-
Family Health Study (Validation of a Family History of Cancer Questionnaire for Risk Factor Surveillance)
NCT00341757 ·Status: COMPLETED
-
Clinical and Laboratory Analysis of Familial Cancer
NCT02565004 ·Status: COMPLETED
-
Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers
NCT00579163 ·Status: ACTIVE_NOT_RECRUITING
-
Biology Studies of Hematologic Cancers
NCT00923442 ·Status: ENROLLING_BY_INVITATION
-
Genomic Analysis of Families With a History of Discordant Cancers
NCT04860453 ·Status: RECRUITING
-
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance
NCT00026663 ·Status: COMPLETED
-
Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
NCT03739827 ·Status: RECRUITING
-
Biomarkers in Tumor Tissue Samples From Patients With Peripheral T-cell Lymphoma or Natural Killer Cell Neoplasms
NCT01390597 ·Status: COMPLETED
-
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
NCT02269592 ·Status: RECRUITING
-
Circulating Tumor Cells in Solid Tumors
NCT03161821 ·Status: COMPLETED
-
Studying Genes Associated With Non-Hodgkin Lymphoma in Young Patients
NCT01623856 ·Status: COMPLETED
-
Collection of Blood From Patients With Cancer
NCT00034216 ·Status: RECRUITING
-
Discovering New Genetic Markers in Adults and Children Who May Be At Risk for Hereditary Forms of Cancer
NCT03922893 ·Status: RECRUITING
-
Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom
NCT00757614 ·Status: UNKNOWN
-
Genetic Study of Chronic Lymphocytic Leukemia Families
NCT00503256 ·Status: UNKNOWN
-
Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions
NCT00436696 ·Status: COMPLETED
-
S9704-S0014-S0313A Studying Genes in Samples From Patients With Limited or Advanced Diffuse Large B-Cell Lymphoma
NCT01563861 ·Status: COMPLETED
-
Study of Natural Killer Cells in Bone Marrow and Blood Samples From Patients With and Without Hematologic Cancer
NCT00918658 ·Status: TERMINATED
-
Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia
NCT01005368 ·Status: COMPLETED
-
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069 ·Status: RECRUITING
-
Blood Brain Barrier Differences in Patients with Brain Tumors Undergoing Surgery
NCT03071913 ·Status: COMPLETED
-
Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment
NCT02105168 ·Status: UNKNOWN ·Phase: NA
-
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
NCT06736613 ·Status: RECRUITING ·Phase: PHASE2
-
Cell-free DNA in Hereditary And High-Risk Malignancies 1
NCT04261972 ·Status: ACTIVE_NOT_RECRUITING